Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Alnylam Pharmaceuticals's 3-Year RORE % for the quarter that ended in Mar. 2026 was -782.72%.
The industry rank for Alnylam Pharmaceuticals's 3-Year RORE % or its related term are showing as below:
LTS:0HD2's 3-Year RORE % is ranked worse than 99.54% of 1291
companies
in the Biotechnology industry
Industry Median: -11.44
vs LTS:0HD2: -782.72
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Alnylam Pharmaceuticals 3-Year RORE % Related Terms
Alnylam Pharmaceuticals 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HD2 vs RVMD, ONC, MRNA: 3-Year RORE % Comparison
For the Biotechnology subindustry, Alnylam Pharmaceuticals's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Alnylam Pharmaceuticals (LTS:0HD2) has a 3-Year RORE % of -782.72 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Alnylam Pharmaceuticals and its competitors. According to the industry distribution chart, Alnylam Pharmaceuticals ranks #1285 out of 1291 companies in the Biotechnology industry, placing it in the top 99.5%.
Is Alnylam Pharmaceuticals' 3-Year RORE % too high?
Alnylam Pharmaceuticals' current 3-Year RORE % is -782.72. Based on the distribution chart, Alnylam Pharmaceuticals ranks #1285 out of 1291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alnylam Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' 3-Year RORE % compare to RVMD and ONC?
According to the Biotechnology industry distribution chart, Alnylam Pharmaceuticals ranks #1285 out of 1291 companies for 3-Year RORE %. This places Alnylam Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Alnylam Pharmaceuticals and its competitors. Alnylam Pharmaceuticals's current 3-Year RORE % is -782.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $518.90, compared to a current price of $302.90 — trading 41.6% below its estimated fair value. The current 3-Year RORE % is -782.72. Alnylam Pharmaceuticals' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current 3-Year RORE % is -782.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of $302.90 is trading 41.6% below its estimated GF Value™ of $518.90.
GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for LTS:0HD2:
3-Year RORE %: -782.72
GF Value™: $518.90 vs. price of $302.90 (41.6% below fair value)
No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
67GF Score
Get the complete analysis for LTS:0HD2
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HD2 has been successfully added to your 
